Publicaciones en colaboración con investigadores/as de VU University Medical Center (11)

2021

  1. Finding our way through the labyrinth of dementia biomarkers

    European Journal of Nuclear Medicine and Molecular Imaging

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. COVID-19 and the brain: impact on nuclear medicine in neurology

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

    European Journal of Nuclear Medicine and Molecular Imaging

2019

  1. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 3, pp. 540-557

2017

  1. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (European Journal of Nuclear Medicine and Molecular Imaging, (2017), 44, 3, (353-357), 10.1007/s00259-016-3589-9)

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Position statement on radiopharmaceutical production for clinical trials

    EJNMMI Radiopharmacy and Chemistry, Vol. 2, Núm. 1

  3. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis

    European Journal of Nuclear Medicine and Molecular Imaging

2015

  1. A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: A concise overview and practical guidance for a risk-based approach

    Nuclear Medicine Communications, Vol. 36, Núm. 5, pp. 414-422

2014

  1. Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals

    European Journal of Nuclear Medicine and Molecular Imaging